Biotherapeutics company PureTech Health plc (Nasdaq: PRTC) (LSE: PRTC) announced on Wednesday that it has presented new Phase 2b analyses demonstrating that its investigational therapy deupirfenidone (LYT-100) maintained consistent safety and efficacy in older patients with idiopathic pulmonary fibrosis (IPF), including those aged 75 and above. Findings were shared at the American College of Chest Physicians (CHEST) 2025 Annual Meeting.

Results from the Phase 2b ELEVATE IPF trial showed that deupirfenidone was well tolerated across age groups, with rates of treatment-emergent adverse events, such as nausea, comparable between older and younger patients. Efficacy outcomes aligned with previously reported data, further reinforcing deupirfenidone's differentiated clinical profile.

ELEVATE IPF was a randomised, double-blind, placebo-and active-controlled study evaluating two doses of deupirfenidone against pirfenidone and placebo. The analysis addressed a key treatment gap in IPF, as older patients are often undertreated due to tolerability concerns.

Deupirfenidone, a deuterated form of pirfenidone, is being developed as a potential new standard of care for IPF. Earlier trial data indicated its ability to slow lung function decline while maintaining strong tolerability over 26 weeks, with ongoing studies suggesting sustained benefit beyond 52 weeks.

The therapy is being advanced by Celea Therapeutics, a PureTech-founded company focused on respiratory diseases. PureTech Health's hub-and-spoke model enables the development of such assets through capital-efficient structures, with three FDA-approved therapies already emerging from its pipeline.